Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 1/20 | 0.42 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.40 |
| ▸ | PDE4A | P27815 | 4/20 | 0.37 |
| ▸ | PDE4B | Q07343 | 4/20 | 0.37 |
| ▸ | PDE4C | Q08493 | 4/20 | 0.37 |
| ▸ | PDE4D | Q08499 | 4/20 | 0.37 |
| ▸ | USP2 | O75604 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | BUB1 | O43683 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | THRB | P10828 | 1/20 | 0.35 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.34 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.34 |
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.34 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.33 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17107637 | 0.91 | KDM1A (0.38) | KDM1AUSP30PDE4APDE4BPDE4C | |
| SCHEMBL20456330 | 0.87 | KDM1A (0.43) | KDM1AUSP30PDE4APDE4BPDE4C | |
| SCHEMBL21408126 | 0.84 | KDM1A (0.41) | KDM1AUSP30PDE4APDE4BPDE4C | |
| SCHEMBL25232243 | 0.84 | KDM1A (0.41) | KDM1AUSP30PDE4APDE4BPDE4C | |
| SCHEMBL25281708 | 0.83 | KDM1A (0.40) | KDM1AUSP30PDE4APDE4BPDE4C | |
| SCHEMBL21408149 | 0.82 | KDM1A (0.41) | KDM1AUSP30PDE4APDE4BPDE4C | |
| SCHEMBL29348862 | 0.82 | USP2 (0.41) | KDM1AUSP30PDE4APDE4BPDE4C | |
| SCHEMBL17113437 | 0.81 | KDM1A (0.39) | KDM1AUSP30PDE4APDE4BPDE4C | |
| SCHEMBL23051644 | 0.78 | USP30 (0.38) | KDM1AUSP30PDE4APDE4BPDE4C | |
| SCHEMBL16914261 | 0.78 | USP30 (0.44) | USP30USP2SMN1; SMN2KDM4EMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3810615-B1 | ARGINASE INHIBITORS AND METHODS OF USE | MERCK SHARP & DOHME LLC (US) | 2026-01-28 | — | — | EP | disclosed |
| US-20250136611-A1 | HETEROBIFUNCTIONAL COMPOUNDS AND METHODS OF TREATING DISEASE | HALDA THERAPEUTICS OPCO, INC. | 2025-05-01 | — | — | US | disclosed |
| WO-2025085738-A1 | HETEROBIFUNCTIONAL COMPOUNDS AND METHODS OF TREATING DISEASE | HALDA THERAPEUTICS OPCO, INC. (US) | 2025-04-24 | — | — | WO | disclosed |
| EP-3632907-B1 | N-(AZAARYL)CYCLOLACTAM-1-CARBOXAMIDE DERIVATIVE, PREPARATION METHOD THEREFOR, AND USE THEREOF | ABBISKO THERAPEUTICS CO LTD (CN) | 2024-02-28 | — | — | EP | disclosed |
| EP-3632907-B1 | N-(AZAARYL)CYCLOLACTAM-1-CARBOXAMIDE DERIVATIVE, PREPARATION METHOD THEREFOR, AND USE THEREOF | ABBISKO THERAPEUTICS CO LTD (CN) | 2024-02-28 | — | — | EP | disclosed |
| US-11274111-B2 | Arginase inhibitors and methods of use | MERCK SHARP & DOHME CORP. (US) | 2022-03-15 | — | — | US | disclosed |
| US-11186564-B2 | Dual NAV1.2/5HT2a inhibitors for treating CNS disorders | SUNOVION PHARMACEUTICALS INC. (US) | 2021-11-30 | — | — | US | disclosed |
| US-11186564-B2 | Dual NAV1.2/5HT2a inhibitors for treating CNS disorders | SUNOVION PHARMACEUTICALS INC. (US) | 2021-11-30 | — | — | US | disclosed |
| US-11149021-B2 | N-(azaaryl)cyclolactam-1-carboxamide derivative, preparation method therefor, and use thereof | ABBISKO THERAPEUTICS CO., LTD. (CN) | 2021-10-19 | — | — | US | disclosed |
| US-11149021-B2 | N-(azaaryl)cyclolactam-1-carboxamide derivative, preparation method therefor, and use thereof | ABBISKO THERAPEUTICS CO., LTD. (CN) | 2021-10-19 | — | — | US | disclosed |
| EP-3632907-A1 | N-(AZAARYL)CYCLOLACTAM-1-CARBOXAMIDE DERIVATIVE, PREPARATION METHOD THEREFOR, AND USE THEREOF | Abbisko Therapeutics Co., Ltd. (CN) | 2020-04-08 | — | — | EP | disclosed |
| US-20200071302-A1 | N-(AZAARYL)CYCLOLACTAM-1-CARBOXAMIDE DERIVATIVE, PREPARATION METHOD THEREFOR, AND USE THEREOF | ABBISKO THERAPEUTICS CO., LTD. (CN) | 2020-03-05 | — | — | US | disclosed |
| US-20200071302-A1 | N-(AZAARYL)CYCLOLACTAM-1-CARBOXAMIDE DERIVATIVE, PREPARATION METHOD THEREFOR, AND USE THEREOF | ABBISKO THERAPEUTICS CO., LTD. (CN) | 2020-03-05 | — | — | US | disclosed |
| WO-2019245890-A1 | ARGINASE INHIBITORS AND METHODS OF USE | MERCK SHARP & DOHME CORP. (US) | 2019-12-26 | — | — | WO | disclosed |
| WO-2018214867-A9 | N-(AZAARYL)CYCLOLACTAM-1-CARBOXAMIDE DERIVATIVE, PREPARATION METHOD THEREFOR, AND USE THEREOF | 上海和誉生物医药科技有限公司 | 2019-10-03 | — | — | WO | disclosed |
| WO-2018214867-A9 | N-(AZAARYL)CYCLOLACTAM-1-CARBOXAMIDE DERIVATIVE, PREPARATION METHOD THEREFOR, AND USE THEREOF | 上海和誉生物医药科技有限公司 | 2019-10-03 | — | — | WO | disclosed |
| US-20190194163-A1 | DUAL NAV1.2/5HT2a INHIBITORS FOR TREATING CNS DISORDERS | SUNOVION PHARMACEUTICALS INC. (US) | 2019-06-27 | — | — | US | disclosed |
| US-20190194163-A1 | DUAL NAV1.2/5HT2a INHIBITORS FOR TREATING CNS DISORDERS | SUNOVION PHARMACEUTICALS INC. (US) | 2019-06-27 | — | — | US | disclosed |
| WO-2018026371-A1 | DUAL NAV1.2/5HT2A INHIBITORS FOR TREATING CNS DISORDERS | SUNOVION PHARMACEUTICALS INC. (US) | 2018-02-08 | — | — | WO | disclosed |
| WO-2018026371-A1 | DUAL NAV1.2/5HT2A INHIBITORS FOR TREATING CNS DISORDERS | SUNOVION PHARMACEUTICALS INC. (US) | 2018-02-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200071302-A1 | N-(AZAARYL)CYCLOLACTAM-1-CARBOXAMIDE DERIVATIVE, PREPARATION METHOD THEREFOR, AND USE THEREOF | CSF1R, CSF3R, FAR1 | KDM1A 1490/4885USP30 3929/4885PDE4A 2068/4885 |
| US-20250136611-A1 | HETEROBIFUNCTIONAL COMPOUNDS AND METHODS OF TREATING DISEASE | VHL, BRCA1, TP53 | KDM1A 1304/4885USP30 2289/4885PDE4A 3632/4885 |
| US-11149021-B2 | N-(azaaryl)cyclolactam-1-carboxamide derivative, preparation method therefor, and use thereof | CSF1R, CSF3R, FAR1 | KDM1A 1490/4885USP30 3929/4885PDE4A 2068/4885 |
| US-20190194163-A1 | DUAL NAV1.2/5HT2a INHIBITORS FOR TREATING CNS DISORDERS | SCN2A, HTR2A, HTR2C | KDM1A 2994/4885USP30 4334/4885PDE4A 586/4885 |
| US-11186564-B2 | Dual NAV1.2/5HT2a inhibitors for treating CNS disorders | SCN2A, HTR2A, HTR2C | KDM1A 2994/4885USP30 4334/4885PDE4A 586/4885 |
| US-11274111-B2 | Arginase inhibitors and methods of use | ARG1, ARG2, PRMT1 | KDM1A 1062/4885USP30 2472/4885PDE4A 507/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.